WHO Director General, ex-UK PM urge IP waiver for Covid-19 vaccine

WHO Director-General Tedros Adhanom Ghebreyesus, and former UK Prime Minister Gordon Brown have called for a temporary waiver of intellectual property (IP) rights for Covid-19 vaccines.

Tedros Adhanom Ghebreyesus
WHO Director-General Tedros Adhanom Ghebreyesus. Photo: Bloomberg
IANS Geneva
2 min read Last Updated : May 04 2021 | 9:25 AM IST

World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, and former UK Prime Minister Gordon Brown have called for a temporary waiver of intellectual property (IP) rights for Covid-19 vaccines.

"If we're going to vaccinate majority of the adults to bring herd immunity, then the amount of vaccine we need will be significantly more than what we have now," Xinhua news agency quoted Tedros as saying during a WHO press conference on Monday.

"The production capacity should increase. And that's why the IP waiver will be very important," he said, adding that it wasn't "a charity issue".

A temporary suspension of IP rights for Covid-19 vaccines could be instrumental in vaccine manufacturing "in Africa and in other parts of the world where manufacturing is not happening", said Brown.

Many countries, including South Africa and India, have called for temporarily suspending IP rights for the vaccines to allow production globally.

The World Trade Organization was discussing the IP waiver last week but no definite conclusions have been reached yet in Geneva.

As the UK has taken on the Presidency of the G7 group of nations in 2021 and will host the G7 Summit in June, both Tedros and Brown urged the bloc to make the temporary waiver a reality.

"Next month, leaders from the G7 countries will gather for what may be the most significant meeting in its history. The G7 countries are the world's economic and political leaders. They are also home to many of the world's vaccine producers," Tedros said.

"If we cannot use it now, when can we use it?" asked the WHO chief, stressing that "all options to increase production as soon as possible" should be used.

"The provision of waiving IP was meant for this condition, for emergencies, and this is unprecedented," he noted.

"If they could make a decision that they collectively would support a temporary waiver, I think that'd be a huge advance," Brown stressed.

--IANS

ksk/

 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusWHOWorld Health OrganisationCoronavirus VaccineIntellectual Property Right

First Published: May 04 2021 | 9:10 AM IST

Next Story